A Newly Discovered Form of Cell Death May Help Explain Alzheimer’s Progression

Researchers have identified a previously unknown form of cell death that may help explain why neurons gradually die in Alzheimer's disease and several other neurodegenerative disorders. The newly described process, called karyoptosis, appears to connect the buildup of toxic proteins inside brain cells with the breakdown of the cell nucleus, offering a potential new target for future treatments.

The study, titled "Karyoptosis mediates cell death and neurodegeneration upon proteotoxic stress," was published in Nature Communications. Conducted by scientists at King's College London and the UK Dementia Research Institute, the research provides new insight into one of the fundamental processes that may drive neurodegeneration.

A Newly Identified Mechanism of Cell Death

Neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS) are all characterized by the accumulation of abnormal proteins inside neurons.

As these toxic protein clumps build up, neurons gradually lose their ability to function before eventually dying. This progressive cell loss contributes to symptoms including memory impairment, personality changes, and movement difficulties.

Although several forms of programmed cell death have previously been identified, none has fully explained the widespread neuronal loss seen in these disorders.

The researchers propose that karyoptosis represents a distinct mechanism linking toxic protein accumulation directly to the destruction of the cell nucleus.

How Karyoptosis Damages Neurons

Karyoptosis begins when harmful proteins accumulate within a neuron, triggering a cascade of molecular events.

As the process progresses, the nucleus—the structure that contains the cell's DNA and regulates its activity—gradually shrinks.

Eventually, the nuclear membrane becomes unstable, fragments, and can no longer maintain the integrity of the cell, ultimately leading to neuronal death.

To investigate this process, the researchers analyzed approximately 3,000 brain cells obtained from 28 individuals diagnosed with either frontotemporal dementia or end-stage Alzheimer's disease.

Using advanced computational analyses, they compared these cells with brain tissue from neurologically healthy older adults.

The researchers found evidence of karyoptosis in approximately 35% of cells from the frontal cortex of people with Alzheimer's disease.

By comparison, similar signs appeared in only about 15% of neurons from healthy individuals, suggesting that the process is substantially more active in diseased brains.

A Potential Target for New Treatments

The team also identified a molecular pathway that appears to regulate karyoptosis.

By experimentally inducing protein aggregation in rat neurons—mimicking the toxic protein buildup observed in Alzheimer's disease and related disorders—they were able to trigger nuclear collapse through the newly identified pathway.

Particular attention focused on kinases, enzymes that regulate numerous cellular processes by acting as molecular switches.

Laboratory experiments showed that blocking specific kinases reduced biological markers of karyoptosis while helping preserve the normal structure of the cell nucleus.

One interaction emerged as especially important.

The researchers identified a key role for the interaction between the enzyme p38 MAP kinase and LaminB1, a structural protein that helps maintain the integrity of the nuclear membrane.

Disrupting this interaction reduced signs of nuclear shrinkage and fragmentation, suggesting that it may play a central role in driving karyoptosis.

What the Findings Could Mean

The discovery raises the possibility of developing treatments designed to interrupt karyoptosis before neurons are irreversibly damaged.

Rather than directly removing abnormal proteins, future therapies might target the molecular events that occur after toxic proteins accumulate, potentially slowing the progression of neurodegeneration.

The researchers suggest that selectively disrupting the interaction between p38 MAP kinase and LaminB1 could help preserve neuronal survival while other treatments address the underlying protein abnormalities.

They also believe that understanding the sequence of events involved in karyoptosis may help identify the most effective stage at which therapeutic intervention could occur.

An Early but Promising Discovery

Although the findings offer an important advance in understanding neurodegenerative disease, the research remains at an early stage.

Much of the experimental work was conducted using laboratory models and human brain tissue rather than living patients, meaning further studies will be needed before the discovery can be translated into new treatments.

The study was funded primarily by Alzheimer's Research UK and the Biotechnology and Biological Sciences Research Council, with additional support from the UK Medical Research Council and the UK Dementia Research Institute.

Future research will determine whether therapies targeting karyoptosis can safely slow neuronal loss in people with Alzheimer's disease, frontotemporal dementia, and other neurodegenerative disorders.